Aura Biosciences's Days Sales Outstanding for the
three
months ended in Mar. 2026 was .
Aura Biosciences's Days Inventory for the
three
months ended in Mar. 2026 was .
Aura Biosciences's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, Aura Biosciences's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 0.00.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Aura Biosciences Cash Conversion Cycle Related Terms
Aura Biosciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Aura Biosciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AURA vs NVCT, CADL, OCS: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Aura Biosciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aura Biosciences Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aura Biosciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Aura Biosciences's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Aura Biosciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aura Biosciences (AURA) has a Cash Conversion Cycle of 0.00 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aura Biosciences and its competitors.
Is Aura Biosciences' Cash Conversion Cycle too high?
Aura Biosciences' current Cash Conversion Cycle is 0.00. Overall, Aura Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' Cash Conversion Cycle compare to NVCT and CADL?
Aura Biosciences' Cash Conversion Cycle of 0.00 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aura Biosciences and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aura Biosciences's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Aura Biosciences' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Aura Biosciences (AURA), the current Cash Conversion Cycle is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
35GF Score
Get the complete analysis for AURA
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURA has been successfully added to your 
